Ricky Goldwasser
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
250
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Underweight | $26 → $33 | $42.35 | -22.08% | 8 | Oct 30, 2024 | |
| UNH UnitedHealth Group | Maintains: Overweight | $615 → $610 | $567.56 | +7.48% | 15 | Oct 16, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $12 → $6 | $3.20 | +87.50% | 16 | Jun 28, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.81 | +46.84% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $6.19 | -11.15% | 9 | Nov 10, 2023 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $205 | $180.96 | +13.28% | 19 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $17.65 | -57.51% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $12.95 | -7.34% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $63.52 | +14.92% | 10 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $155.29 | -6.63% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $260 | $227.10 | +14.49% | 14 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $326.75 | +11.71% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $526.34 | -20.20% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $9.00 | +1,233.33% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $260.71 | +137.81% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $414.01 | +20.77% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $55.81 | +122.18% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $316.49 | +0.48% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $116.13 | -39.72% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $9.46 | +312.26% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $135 | $58.73 | +129.87% | 8 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $209.16 | -6.77% | 6 | Oct 21, 2020 |
Doximity
Oct 30, 2024
Maintains: Underweight
Price Target: $26 → $33
Current: $42.35
Upside: -22.08%
UnitedHealth Group
Oct 16, 2024
Maintains: Overweight
Price Target: $615 → $610
Current: $567.56
Upside: +7.48%
Accolade
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $12 → $6
Current: $3.20
Upside: +87.50%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.81
Upside: +46.84%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $6.19
Upside: -11.15%
Charles River Laboratories International
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $220 → $205
Current: $180.96
Upside: +13.28%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $17.65
Upside: -57.51%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $12.95
Upside: -7.34%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $63.52
Upside: +14.92%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $155.29
Upside: -6.63%
Aug 3, 2023
Maintains: Overweight
Price Target: $285 → $260
Current: $227.10
Upside: +14.49%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $326.75
Upside: +11.71%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $526.34
Upside: -20.20%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $9.00
Upside: +1,233.33%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $260.71
Upside: +137.81%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $414.01
Upside: +20.77%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $55.81
Upside: +122.18%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $316.49
Upside: +0.48%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $116.13
Upside: -39.72%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $9.46
Upside: +312.26%
Feb 3, 2021
Maintains: Overweight
Price Target: $115 → $135
Current: $58.73
Upside: +129.87%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $209.16
Upside: -6.77%